C4 Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This annual filing does not provide a separate set of fourth-quarter financial results. C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders; it has no approved products and has not generated product-sales revenue.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $20.8 million | $31.1 million |
| Research and development expense | $117.7 million | $117.8 million |
| General and administrative expense | $42.1 million | $42.8 million |
| Operating loss | $139.0 million | $129.5 million |
| Net loss | $132.5 million | $128.2 million |
| Net loss per share, basic and diluted | $2.67 | $2.62 |
| Net cash used in operating activities | $106.8 million | $105.9 million |
- Revenue and margins: Revenue came from collaboration agreements, not product sales. The filing reports no product-sales gross margin; operating expenses substantially exceeded collaboration revenue.
- Liquidity: Cash, cash equivalents and marketable securities totaled $281.7 million at year-end, including $155.1 million of marketable securities. Current assets were $271.2 million and current liabilities were $42.8 million.
- Debt and commitments: The company repaid the remaining $12.5 million term-loan principal in July 2023, leaving no long-term debt at year-end. It reported $71.0 million of operating lease liabilities, with $89.0 million of undiscounted lease payments remaining.
- Cash flows: Investing activities provided $158.3 million, primarily from net maturities of marketable securities; financing activities provided $45.5 million, principally from $57.7 million of ATM proceeds, partly offset by debt repayment.
Changes versus the prior year
- Collaboration revenue fell $10.3 million, mainly as Biogen and Calico research activity wound down; higher Roche revenue partly offset the declines. Research and development expense was essentially flat, as lower preclinical costs offset increased clinical-trial costs.
- Operating loss increased $9.5 million and net loss increased $4.3 million. Higher interest income partly offset higher operating losses; 2023 also included $1.3 million of income tax expense and a $0.6 million debt-extinguishment loss.
- Marketable securities declined from $307.4 million to $155.1 million, while cash and cash equivalents increased from $29.8 million to $126.6 million. The company raised equity through its ATM program and repaid its term loan.
Business, outlook and notable developments
- Pipeline: CFT7455, an IKZF1/3 degrader, and CFT1946, a BRAF V600X degrader, were in Phase 1/2 trials. CFT8919, an EGFR L858R degrader, was licensed to Betta Pharma for Greater China; the FDA cleared its IND in June 2023 and Betta received China CTA clearance in December.
- Clinical commentary: C4 reported December 2023 dose-escalation data for CFT7455, describing antimyeloma activity and responses in heavily pretreated patients; neutropenia was the most common Grade 3-or-higher adverse event. January 2024 CFT1946 data from the first two cohorts showed dose-proportional exposure and deep BRAF degradation. The filing does not give a clear numerical response rate or full clinical dataset in the supplied text.
- Portfolio and workforce actions: In November 2023, the company decided not to advance CFT8634 beyond Phase 1 dose escalation and accrued $3.1 million of related wind-down costs at year-end. On January 9, 2024, it announced a roughly 30% workforce reduction and estimated $2.7 million of one-time restructuring charges.
- Collaborations and subsequent financing: The December 2023 Merck agreement included a $10 million upfront payment, received in January 2024, and potential milestones and royalties; potential payments could reach approximately $2.5 billion if all three additional target options are exercised. In January 2024, Betta’s affiliate invested $25 million for shares. The company also reported $71.8 million in total net ATM proceeds from shares settled in 2023 and January 2024.
- Runway and guidance: Management stated that year-end funds, January 2024 proceeds and anticipated restructuring savings were expected to fund planned operations into 2027, subject to assumptions. The financial-statement note separately states year-end cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months from issuance. The company cautions that estimates may prove wrong and that additional capital will be needed to take candidates through approval. No specific financial guidance was provided.
- Principal risks: Continued losses and dependence on additional funding; clinical, regulatory and safety uncertainty for an emerging drug modality; reliance on collaborators and third-party manufacturers; competition; intellectual-property risks; and potential pricing, reimbursement and dilution pressures. The company reported no material legal proceedings.
Investor facts to verify
- Review the full CFT7455 and CFT1946 clinical datasets, including patient numbers, response durability, safety, dose selection and subsequent updates.
- Reconcile the stated runway into 2027 with the assumptions behind the estimate, January 2024 cash proceeds, the restructuring savings and ongoing trial costs.
- Track CFT8919’s Betta-led clinical progress, collaboration obligations and any conditions or milestones that could affect economics or timing.
- Assess the consequences of discontinuing CFT8634 and the 2024 workforce reduction for pipeline priorities, execution capacity and future expenses.
- Monitor collaboration revenue, future milestone or royalty receipts, cash burn, financing needs, share-count dilution and the status of patent protection.